Latest News

The accelerating use of virtual trials – have your say in our survey

Take part in GlobalData’s decentralised clinical trials survey here. Since early March 2020, a significant number of companies, including sponsors,…

How to Source Non-IMP Supplies for Clinical Trials

When planning a clinical trial, sometimes the non-investigative medicinal product (non-IMP) supplies are given secondary thought to matters that could…

Sandoz Abandons US Development of Rixathon

Last November, Novartis’ Sandoz division announced that it was no longer pursuing U.S. approval for Rixathon, its biosimilar version of…

GDPR: The Implications for Clinical Development

For those based in Europe, the General Data Protection Regulation (GDPR) came into force across the European Union on May…

Industry Viewpoints: Patient Recruitment and Expanded Access

Elizabeth Williams: Can you provide an insight into the current challenges you face in clinical operations in oncology? Howard Fingert:…

Medical Device Development – Challenges of an SME

The start of any adventure can often come from the most unexpected quarters. A chance meeting at a conference or…

MDMA Treatments Found to Eliminate PTSD Symptoms in Phase II Trial

According to a study published by clinical neuroscience in 2000, statistically, each person has a 50 percent chance of experiencing…

How Whole Systems Thinking Could Transform the Clinical Supply Chain

In 2006, the United States Government Accountability Office (US GAO) issued a report, GAO-07-49, highlighting historical attrition rates in drug…

Managing Blinding Requirements in IRT: An Overview

Global clinical trends show an increasing level of complexity in trial design, adding critical challenges on randomization and information blinding.…

Integrating New Assets: A Supply Chain Perspective

The competitive landscape for biopharmaceuticals always seems to be heating up. Internally developed assets are rarely enough to sustain growth,…